← Leaderboards
Mathew Mark Blurton-Jones
University Of California-Irvine
$14,315,430
Attributed
$20,508,883
Total exposure
13
Grants
11
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.5M · FY2008–25$10M$7.5M$5M$2.5M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$20,508,883 · 13
By mechanism
RF1$12,191,179 · 4
R01$3,450,773 · 2
P50$2,189,852 · 2
P30$1,933,104 · 3
K01$551,553 · 1
R21$192,422 · 1
Top collaborators
- Nicole Gabriele Coufal2 shared
- Robert C Spitale2 shared
- Konstantinos Arfanakis1 shared
- Sunil Gandhi1 shared
- Yadong Huang1 shared
- Julie A Schneider1 shared
- Andrew Chris Yang1 shared
Most similar at University Of California-Irvine
Same institution · by research overlap
- Hayk Davtyan$2,871,844
- Seyed Ahmad Sajjadi$8,712,887
- Seyed Ali Mortazavi$28,674,217
- Wayne W Poon$7,008,264
- Xiaolin Zi$5,893,861
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseasePathologyCellsGenerationsInduced Pluripotent Stem CellGeneticMutationNeuropathologyNeuronsS Disease RiskGenesFibroblastsExhibitsTau ProteinsClustered Regularly Interspaced Short Palindromic RepeatsMicrogliaInnovationCognitiveCell LineCollaborationsResourcesRisk FactorsResearch Personnel
Grant awards (35)
Contribution of AD genetic risk and microglial BIN1 to tauopathy$752,411
R01 · FY2025 · AG
Core F: Induced Pluripotent Stem Cell Core$432,534
P30 · FY2025 · AG · contact PI
Vascular-immune mechanisms of cerebral amyloid angiopathy and Alzheimer's pathology$5,423,836
RF1 · FY2024 · NS
Contribution of AD genetic risk and microglial BIN1 to tauopathy$767,112
R01 · FY2024 · AG
Core F: Induced Pluripotent Stem Cell Core$274,750
P30 · FY2024 · AG · contact PI
Core F: Induced Pluripotent Stem Cell Core$438,540
P30 · FY2023 · AG · contact PI
Core F: Induced Pluripotent Stem Cell Core$234,313
P30 · FY2022 · AG · contact PI
ENGINEERED HUMAN MICROGLIA AS A CELL-BASED THERAPY FOR A-BETA PLAQUE REMOVAL$192,422
R21 · FY2022 · AG · contact PI
Manipulating DNA repair enzymes to examine the interactions between aging and Alzheimers disease with iPSC-derived microglia$386,250
R01 · FY2021 · AG · contact PI
Core F: Induced Pluripotent Stem Cell Core$278,363
P30 · FY2021 · AG · contact PI
A novel platform for the investigation of human microglia$156,342
RF1 · FY2021 · DA
Manipulating DNA repair enzymes to examine the interactions between aging and Alzheimers disease with iPSC-derived microglia$386,250
R01 · FY2020 · AG · contact PI
Core F: Induced Pluripotent Stem Cell Core$274,604
P30 · FY2020 · AG · contact PI
A novel platform for the investigation of human microglia$1,980,790
RF1 · FY2019 · DA · contact PI
Manipulating DNA repair enzymes to examine the interactions between aging and Alzheimers disease with iPSC-derived microglia$386,250
R01 · FY2019 · AG · contact PI
Core F: iPS Cell Core$230,812
P50 · FY2019 · AG · contact PI
Manipulating DNA repair enzymes to examine the interactions between aging and Alzheimers disease with iPSC-derived microglia$386,250
R01 · FY2018 · AG · contact PI
Core F: iPS Cell Core$230,812
P50 · FY2018 · AG · contact PI
Examining the role of adaptive immunity in Alzheimer's Disease pathogenesis$2,708,461
RF1 · FY2017 · AG · contact PI
Manipulating DNA repair enzymes to examine the interactions between aging and Alzheimers disease with iPSC-derived microglia$386,250
R01 · FY2017 · AG · contact PI
Core F: iPS Cell Core$230,813
P50 · FY2017 · AG · contact PI
Core F: iPS Cell Core$230,812
P50 · FY2016 · AG · contact PI
Core F: iPS Cell Core$230,812
P50 · FY2015 · AG · contact PI
The role of TREM2 in human microglial function and Alzheimer disease pathogenesis$1,921,750
RF1 · FY2014 · AG · contact PI
NEURAL STERM CELLS TO TREAT AND MODEL ALZHEIMER DISEASE$234,382
P50 · FY2014 · AG · contact PI
NEURAL STERM CELLS TO TREAT AND MODEL ALZHEIMER DISEASE$179,495
P50 · FY2013 · AG · contact PI
NEURAL STERM CELLS TO TREAT AND MODEL ALZHEIMER DISEASE$46,387
P50 · FY2013 · AG · contact PI
NEURAL STERM CELLS TO TREAT AND MODEL ALZHEIMER DISEASE$194,941
P50 · FY2012 · AG · contact PI
The Role of Beta-Amyloid Assembly States in Tau Pathology and Cognitive Decline$115,631
K01 · FY2012 · AG · contact PI
NEURAL STERM CELLS TO TREAT AND MODEL ALZHEIMER DISEASE$189,336
P50 · FY2011 · AG · contact PI
The Role of Beta-Amyloid Assembly States in Tau Pathology and Cognitive Decline$112,892
K01 · FY2011 · AG · contact PI
NEURAL STERM CELLS TO TREAT AND MODEL ALZHEIMER DISEASE$191,250
P50 · FY2010 · AG · contact PI
The Role of Beta-Amyloid Assembly States in Tau Pathology and Cognitive Decline$110,233
K01 · FY2010 · AG · contact PI
The Role of Beta-Amyloid Assembly States in Tau Pathology and Cognitive Decline$107,651
K01 · FY2009 · AG · contact PI
The Role of Beta-Amyloid Assembly States in Tau Pathology and Cognitive Decline$105,146
K01 · FY2008 · AG · contact PI